This study investigates solid tumors with specific mutations in the KRAS gene. Researchers are exploring how a medication called ASP5834 can interact with these mutations.
The purpose of this study is to evaluate the safety and tolerability of ASP5834, both alone and in combination with another treatment. Researchers want to determine the appropriate dose of ASP5834 for further studies.
- Who can participate: Adults with locally advanced, unresectable, or metastatic solid tumors with specific KRAS mutations may join, provided they have tried standard treatments or are ineligible for them.
- Study details: Participants will receive ASP5834, either alone or with another medication, through an infusion. Researchers will monitor for any medical issues during the treatment.
- Study timelines: The study will last about 1 year.
How understandable was the trial content above?
Hard to understand
Easy to understand